10 employees
Non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
2016
$20M
from 2 investors over 2 rounds
MAVUPHARMA, INC. raised $20M on November 29, 2017
Investors: Alpine BioVentures and Frazier Healthcare Partners